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atrogenic hypoglycemia is a major limiting factor in
the strict glycemic management of diabetes (1,2).
Hypoglycemia can cause recurrent morbidity in
many people with type 1 diabetes and also in some
with advanced type 2 diabetes (2,3). Rarely fatal, fear of
hypoglycemia precludes maintenance of euglycemia over
a lifetime with diabetes and full realization of the vascular
beneﬁts of glycemic control. Hypoglycemic events com-
promise defenses against subsequent falling plasma glu-
cose concentrations and thus cause a vicious cycle of
recurrent hypoglycemia.
Hypoglycemia in diabetes is fundamentally the result of
episodes of therapeutic hyperinsulinemia caused by treat-
ment with an insulin secretagogue or insulin. In general,
the incidence of iatrogenic hypoglycemia is a function of
the degree of -cell failure (1,2,4), and risk is predicted
by the absence of evidence of endogenous insulin secre-
tion (C-peptide) (5). Incidence of hypoglycemia is lower in
people with type 2 diabetes, who are not usually com-
pletely insulin deﬁcient, than in those with type 1 diabetes,
and this is especially true early in the course of type 2
diabetes. However, the incidence of hypoglycemia in-
creases progressively over time (6), ultimately approxi-
mating that in those with type 1 diabetes (7,8), as type 2
diabetic individuals approach the insulin-deﬁcient end of
the spectrum. Because type 2 diabetes is 20-fold more
prevalent than type 1 diabetes and many people with
type 2 diabetes ultimately require treatment with insu-
lin, most episodes of iatrogenic hypoglycemia, including
severe hypoglycemia, occur in those with type 2 diabe-
tes (1–3,9).
The key physiological defenses against falling plasma
glucose concentrations are 1) a decrease in insulin secre-
tion; 2) an increase in glucagon secretion; and, in the
absence of the latter, 3) an increase in epinephrine secre-
tion (1,2). The behavioral defense is carbohydrate inges-
tion prompted by perception of the largely sympathetic
neural neurogenic symptoms that cause the individual to
become aware of hypoglycemia (10,11). Although these
mechanisms are intact early in the course of type 2
diabetes when endogenous insulin deﬁciency is only rela-
tive, the insulin and glucagon responses are typically
compromised in people with absolute endogenous insulin
deﬁciency in type 1 diabetes (1,2,12) and in those with
advanced type 2 diabetes (13). Epinephrine, sympathetic
nervous system, and symptomatic responses are further
compromised in a subset of patients, causing, in large part,
the clinical syndrome of hypoglycemia unawareness with
a greatly increased risk of severe hypoglycemic episodes
(14). Because experimentally induced recent antecedent
hypoglycemia (as well as exercise and the state of deep
sleep) produces defective epinephrine, sympathetic neu-
ral, and symptom responses to subsequent hypoglycemia
(15,16) and to underscore the key role of the attenuated
sympathoadrenal responses in defense against severe hy-
poglycemia, this pathophysiology has been termed hypo-
glycemia-associated autonomic failure (HAAF) in diabetes
(1,2,13). The attenuated epinephrine secretory response
causes defective glucose counterregulation in the setting
of absolute -cell failure. The concept of HAAF was
developed in the context of type 1 diabetes (1,2), and its
role in the pathogenesis of hypoglycemia in type 2 diabetes
(1,2,9) remains to be clariﬁed.
As reported in this issue of Diabetes, Davis et al. (17)
address this issue, studying 15 patients with relatively
early type 2 diabetes. Mean duration of known diabetes
was only 6 years. At baseline patients had no evidence of
compromised physiological or behavioral defenses against
hypoglycemia. Even after overnight insulin infusions to
maintain near euglycemia, mean fasting plasma C-peptide
concentrations were higher than those of patients with
type 1 diabetes (18,19). Importantly, insulin secretion as
assessed by C-peptide levels fell appropriately, by 75%,
when plasma glucose concentrations were lowered to 3.3
mmol/l (60 mg/dl), just below the postabsorptive physio-
logical range of 3.9–6.1 mmol/l (70–110 mg/dl). At a
plasma glucose concentration of 3.3 mmol/l (60 mg/dl),
increments in plasma glucagon and epinephrine were
similar to those of nondiabetic control patients, and mus-
cle sympathetic nerve activity (MSNA) and symptomatic
responses were enhanced. Perhaps this reﬂects the expe-
rience of hyperglycemia, as the mean A1C was just over
10%, indicating very poor glycemic control. Exaggerated
counterregulatory response to hypoglycemia in those with
type 2 diabetes has been described previously (20).
In the patients with poor glycemic control in Davis et
al.’s study, two episodes of subphysiological plasma glu-
cose concentrations reduced an array of responses (in-
cluding glucagon and epinephrine, MSNA, and symptoms)
to hypoglycemia the following day (17). This has been well
documented in nondiabetic subjects and those with type 1
and type 2 diabetes (1,2,12). However, it is of interest that
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levels as high as 3.3 mmol/l (60 mg/dl) (17).
The novelty of the Davis et al. study is that, following the
ﬁrst hypoglycemia investigation, patients were brought
into strict glycemic control with intensiﬁcation of lifestyle
and oral agent therapy, reducing mean A1C levels to 6.7%
in 6 months with, remarkably, no overall weight gain.
Treatment was associated with an increase in self-re-
ported glucose levels 3.9 mmol/l (70 mg/dl) from 1.1 to
3.2 per patient per month on intensive home monitoring,
although only four patients reported glucose levels 2.8
mmol/l (50 mg/dl). Unfortunately, the extent to which any
of these were symptomatic was not reported, and it is not
clear that the self-monitoring was as intensive before the
intensiﬁcation of therapy. There were no episodes of
major hypoglycemia. This change in glycemic experience
was associated with a substantial reduction in the plasma
epinephrine, MSNA, and symptomatic responses to plasma
glucose concentrations of 3.3 mmol/l (60 mg/dl) (50, 66,
and 40%, respectively), a novel ﬁnding in early type 2
diabetes, although it has been shown in advanced type 2
diabetes that required insulin to improve control (21).
Notably, in the Davis et al. study, decrements in insulin
secretion and increments in glucagon secretion were not
reduced, and only the epinephrine responses were re-
duced signiﬁcantly compared with those of healthy control
subjects.
Coupled with reports of other investigators cited by
Davis et al. (17), these data provide further insight into the
pathophysiology of glucose counterregulation in diabetes
by the application of state-of-the-art assessment methods
in a clinically relevant setting. The data provide both
further documentation that sympathoadrenal and symp-
tomatic responses to hypoglycemia are exaggerated in
early type 2 diabetic patients with poor glycemic control
and new evidence that aggressive glycemic therapy in
these patients results in attenuation of responses to sub-
sequent low plasma glucose concentrations (17). This
effect is most plausibly attributed to reduced exposure to
hyperglycemia and an increased frequency of subphysi-
ological glucose levels during intensive therapy. Further,
immediately antecedent iatrogenic hypoglycemia causes a
further reduction in the vigor of the counterregulatory
responses.
Are there clinical implications from these data? Hypo-
glycemia sufﬁcient to cause cognitive impairment (not
measured by Davis et al.) can diminish quality of life.
Functional sympathoadrenal failure might be relevant to
the pathogenesis of rare, but potentially fatal, ventricular
arrhythmias (22). Concern has arisen about the possible
involvement of hypoglycemia in the adverse effects of
rapid intensiﬁcation of diabetes therapies in late and
complicated type 2 diabetes (23,24). In the present study,
it is noteworthy that in patients with relatively early type 2
diabetes the changes seen in the responses to experimen-
tally induced hypoglycemia were not associated with an
increased frequency of major clinical hypoglycemia, per-
haps because -cell failure was not sufﬁcient to cause loss
of the insulin and glucagon responses (1,2). Data from
follow-up studies show the prolonged beneﬁt of early
intensive glucose management in preventing vascular
complications of diabetes (25,26). These data, taken in
context with other published work showing possible
problems of taking action much later in the course of
the disease, would seem to be a further encouragement
to implementing good control of diabetes as early as
possible.
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